KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Inventory (2016 - 2026)

Biocryst Pharmaceuticals filings provide 12 years of Change in Inventory readings, the most recent being $515000.0 for Q4 2025.

  • On a quarterly basis, Change in Inventory fell 76.19% to $515000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 60.64% decrease, with the full-year FY2025 number at $1.6 million, down 60.64% from a year prior.
  • Change in Inventory hit $515000.0 in Q4 2025 for Biocryst Pharmaceuticals, down from $1.7 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $7.2 million in Q2 2022 to a low of -$1.9 million in Q1 2021.
  • Median Change in Inventory over the past 5 years was $1.2 million (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Change in Inventory: crashed 178.19% in 2023 and later surged 1031.3% in 2024.
  • Biocryst Pharmaceuticals' Change in Inventory stood at $2.1 million in 2021, then crashed by 45.72% to $1.2 million in 2022, then tumbled by 178.19% to -$907000.0 in 2023, then skyrocketed by 338.48% to $2.2 million in 2024, then plummeted by 76.19% to $515000.0 in 2025.
  • The last three reported values for Change in Inventory were $515000.0 (Q4 2025), $1.7 million (Q3 2025), and -$1.4 million (Q2 2025) per Business Quant data.